Ayswarya Kannan1, Lalitha Biswas2, Anil Kumar1, Jessy Kurian3, Anjaly S Nair4, Parasmal Suresh2, Shine Sadasivan5, Raja Biswas2. 1. Amrita Vishwa Vidyapeetham, Amrita Institute of Medical Sciences, Department of Microbiology, Ponekara, Kochi, Kerala, India. 2. Amrita Vishwa Vidyapeetham, Center for Nanoscience and Molecular Medicine, Ponekara, Kochi , Kerala, India. 3. Amrita Vishwa Vidyapeetham, Amrita Institute of Medical Sciences, Molecular biology laboratory, Ponekara, Kochi , Kerala, India. 4. Amrita Vishwa Vidyapeetham, Amrita Institute of Medical Sciences, Department of Biostatistics, Ponekara, Kochi, Kerala, India. 5. Amrita Vishwa Vidyapeetham, Amrita Institute of Medical Sciences, Department of Gastroenterology, Ponekara, Kochi, Kerala, India.
Abstract
INTRODUCTION: We compared the hepatitis C virus (HCV) core antigen test with the HCV RNA assay to confirm anti-HCV results to determine whether the HCV core antigen test could be used as an alternative confirmatory test to the HCV RNA test. METHODS: Sera from 156 patients were analyzed for anti-HCV and HCV core antigen using a chemiluminescent microparticle immunoassay (Architect i2000SR) and for HCV RNA using the artus HCV RG RT-PCR Kit (QIAGEN) in a Rotor-Gene Q instrument. RESULTS: The diagnostic sensitivity, specificity, and positive and negative predictive values of the HCV core antigen assay compared to the HCV RNA test were 77.35%, 100%, 100%, and 89.38%, respectively. HCV core antigen levels showed a good correlation with those from HCV RNA quantification (r =0.872). However, 13 samples with a viral load of less than 4000 IU/mL were negative in the HCV core antigen assay. All gray-zone reactive samples were also RNA positive and were positive on repeat testing. CONCLUSIONS: The Architect HCV core antigen assay is highly specific and has an excellent positive predictive value. At the present level of sensitivity (77%), the study is still relevant in a low-income setting in which most of the HCV-positive patients would go undiagnosed, since HCV RNA testing is not available and/or not affordable. HCV core antigen testing can also help determine the true burden of infection in a population, considering the fact that almost 50% of the anti-HCV positive cases are negative for HCV RNA.
INTRODUCTION: We compared the hepatitis C virus (HCV) core antigen test with the HCV RNA assay to confirm anti-HCV results to determine whether the HCV core antigen test could be used as an alternative confirmatory test to the HCV RNA test. METHODS: Sera from 156 patients were analyzed for anti-HCV and HCV core antigen using a chemiluminescent microparticle immunoassay (Architect i2000SR) and for HCV RNA using the artus HCV RG RT-PCR Kit (QIAGEN) in a Rotor-Gene Q instrument. RESULTS: The diagnostic sensitivity, specificity, and positive and negative predictive values of the HCV core antigen assay compared to the HCV RNA test were 77.35%, 100%, 100%, and 89.38%, respectively. HCV core antigen levels showed a good correlation with those from HCV RNA quantification (r =0.872). However, 13 samples with a viral load of less than 4000 IU/mL were negative in the HCV core antigen assay. All gray-zone reactive samples were also RNA positive and were positive on repeat testing. CONCLUSIONS: The Architect HCV core antigen assay is highly specific and has an excellent positive predictive value. At the present level of sensitivity (77%), the study is still relevant in a low-income setting in which most of the HCV-positive patients would go undiagnosed, since HCV RNA testing is not available and/or not affordable. HCV core antigen testing can also help determine the true burden of infection in a population, considering the fact that almost 50% of the anti-HCV positive cases are negative for HCV RNA.
Authors: H D J Daniel; P Vivekanandan; S Raghuraman; G Sridharan; G M Chandy; P Abraham Journal: Indian J Med Microbiol Date: 2007-01 Impact factor: 0.985
Authors: Oluwaseun Falade-Nwulia; Catalina Suarez-Cuervo; David R Nelson; Michael W Fried; Jodi B Segal; Mark S Sulkowski Journal: Ann Intern Med Date: 2017-03-21 Impact factor: 25.391
Authors: Wenqian Xu; Elena Ivanova Reipold; Peizhen Zhao; Weiming Tang; Joseph D Tucker; Jason J Ong; Jinshen Wang; Philippa Easterbrook; Cheryl Case Johnson; Muhammad S Jamil; Cheng Wang Journal: Front Public Health Date: 2022-05-31